PROTAC erf3a Degrader-2

• UNSPSC Description:

  PROTAC erf3a Degrader-2 (Compound C59) is an orally active PROTAC erf3a Degrader. PROTAC erf3a Degrader-2 inhibits protein expression of SRD5A3 and GSPT1(eRF3a). PROTAC erf3a Degrader-2 inhibits cancer cell proliferation (eg: 22Rv1). PROTAC erf3a Degrader-2 can be used for research of prostate cancer, ovarian cancer, liver cancer, cervical cancer, leukemia, breast cancer. (Red: erf3a ligand (HY-13778); Black: linker (HY-163960); Blue: E3 ligase ligand (HY-W763812))[1].

• Target Antigen:

  PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-erf3a-degrader-2.html

• Smiles:

  O=C(N1C2C(NC(CC2)=O)=O)C3=CC=CC(N[C@H](CCC4)C[C@@H]4NC5=CC(NC([C@H]6CC[C@]([C@@]7([H])[C@@](CC8)([H])[C@@]9([C@@](NC(C=C9)=O)([H])CC7)C)([H])[C@]86C)=O)=CC=C5)=C3C1=O

• Molecular Weight:

  760.92

• References & Citations:

  [1]Guangliang Yu, et al. Medicine for treating human tumor by eRF3a targeting protein degradation mechanism. Patent. CN117801051A.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3033871-15-4